Spyre Therapeutics SYRE Cash Flow Statement (2015-2026)

NASDAQ SYRE
$89.03 +4.31 (+5.09%)
At close: Sep 30, 2026 · 4:00 PM EDT
Reported Financials

Spyre Therapeutics Quarterly Cash Flow Statement

Periods 46 quarters
Latest Jun 2026

Spyre Therapeutics reported cash from operations of -$69.88M and free cash flow of -$69.88M for the quarter ended Jun 2026, down 50.1% year over year. This cash flow statement covers 46 quarters of results from Mar 2015 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-20.31M-20.45M-24.44M-22.32M-18.23M-18.82M-18.42M-217.08M-40.11M-63.18M-43.86M-38.84M-69.03M-56.30M-44.77M-36.72M-11.18M-62.53M-69.00M-36.20M
Share-based Compensation
2.11M2.09M2.10M2.02M1.57M1.43M1.71M1.90M4.80M17.27M13.84M8.70M13.10M9.22M8.86M9.38M9.57M9.81M12.81M13.51M
Gains from Sales and Divestitures
14.61M1.84M10.00M30.00M40.00M
Cash from Operations
-17.00M-19.27M-26.26M-20.67M-15.07M-18.14M-17.63M-16.64M-34.60M-31.04M-28.54M-62.25M-29.42M-37.20M-40.99M-46.56M-37.12M-44.58M-57.37M-69.88M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Depreciation & Amortization
0.41M0.41M0.40M0.38M0.40M0.39M0.38M0.36M
Change in Working Capital
Change in Receivables
0.81M0.20M-0.53M0.19M-0.29M-0.04M1.32M-1.48M-0.16M
Change in Account Payables
-0.34M1.46M-0.34M-1.01M2.21M-3.50M1.38M0.66M-4.16M-0.29M-6.51M-6.40M-2.23M-0.84M3.02M0.02M3.75M1.45M-3.21M0.03M
Change in Accured Expenses
1.04M0.46M-3.14M2.26M-0.42M0.45M-3.16M2.11M-2.94M-0.89M8.15M-15.77M7.37M14.87M-6.00M-2.30M4.41M3.12M3.65M-3.43M
Other Working Capital Changes
-1.40M-2.83M-0.77M3.19M0.44M-1.72M-0.62M-2.75M0.06M0.07M0.38M7.11M-3.28M-1.27M-0.46M4.25M6.16M2.88M0.23M5.61M
Investing Activities
Capital Expenditures
0.09M0.04M0.00M
Sales of Property, Plant and Equipment
0.50M
Change in Intangibles
7.00M30.00M40.00M
Cash from Investing Activities
5.78M9.66M25.76M0.75M16.50M14.00M17.75M6.76M-97.63M-35.27M-104.96M-120.52M42.74M-170.54M-0.06M79.00M25.00M-247.41M56.58M-297.90M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt Repayments
0.11M0.17M0.17M0.17M0.06M0.01M0.01M0.01M
Change in Capital Stock
Net Equity Issued and Repurchased
1.25M0.25M0.18M0.04M0.02M0.10M0.28M169.21M-0.14M-0.22M-161.34M0.22M0.73M0.61M1.75M2.68M432.56M
Misc.
Cash from Financing Activities
1.14M0.08M0.01M42.80M-0.13M-0.01M0.01M209.99M-12.53M163.61M172.16M0.36M12.78M225.60M0.12M0.73M-4.64M312.81M12.26M432.60M
Exchange Rate Effect
-0.03M0.00M-0.02M-0.07M-0.06M0.05M0.01M0.01M-0.02M0.02M-0.00M0.02M-0.01M
Change in Cash
-10.11M-9.52M-0.52M22.81M1.24M-4.10M0.14M200.12M-144.78M97.32M38.66M-182.41M26.11M17.84M-40.93M33.17M-16.76M20.82M11.46M64.82M
Free Cash Flow
-17.09M-19.27M-26.30M-20.67M-15.07M-18.14M-17.63M-16.64M-34.60M-31.04M-28.54M-62.25M-29.42M-37.20M-40.99M-46.56M-37.12M-44.58M-57.37M-69.88M
Net Cash Flow
-10.08M-9.53M-0.49M22.88M1.30M-4.15M0.13M200.11M-144.76M97.30M38.66M-182.41M26.10M17.86M-40.93M33.17M-16.76M20.82M11.46M64.82M

Spyre Therapeutics Cash Flow Statement API

Pull Spyre Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=SYRE&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY